Table 1.

FDA-approved indications for PARP inhibitors in ovarian cancer.

PARP Inhibitor	FDA Approved Indication	Year	Important Trials	References
Olaparib	Single agent treatment for recurrent or progressive ovarian cancer with a germline BRCA mutation and ≥ 3 prior lines of treatment	2014	Phase 2 Proof of Concept Study, Phase 2 Study of Olaparib in Advanced Solid Tumors	[66,67]
	Maintenance therapy after response to platinum-based chemotherapy in platinum sensitive recurrent ovarian cancer irrespective of BRCA status	2017	Study 19, SOLO-2	[68,69,70]
	Maintenance therapy after response to first-line chemotherapy in patients with germline or somatic BRCA mutations	2018	SOLO-1	[71]
Rucaparib	Single agent treatment for recurrent or progressive platinum-sensitive ovarian cancer with a somatic or germline BRCA mutation and ≥ 2 prior lines of treatment	2016	ARIEL-2	[72]
	Maintenance therapy after response to platinum-based chemotherapy in platinum sensitive recurrent ovarian cancer irrespective of BRCA status	2018	ARIEL-3	[73]
Niraparib	Maintenance therapy for recurrent ovarian cancer after complete or partial response to previous platinum-based chemotherapy	2017	NOVA	[74]
	Single agent treatment for recurrent HRD-positive ovarian cancer and ≥ 3 prior lines of treatment	2019	QUADRA	[75]